Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.12.19
Views: 285

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Dr Siddhartha Ganguly speaks to ecancer at the 2019 ASH meeting in Orlando about the Quantum-R trial evaluating clinical outcomes and characteristics of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemotherapy.

He explains that patients who had received quizartinib were much more likely to have received transplantation, this seemed to be due to the complete remission rate was much higher in the quizartinib arm giving them a window of opportunity to take them to the allergenic stem cell transplantation.

Dr Ganguly also reports that patients who received the transplant had a significant survival benefit over those that did not.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation